Trial Profile

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Feb 2023 Results of pooled analysis assessing the tumor mutational burden (TMB) and outcomes in the phase 2 HAWK/CONDOR (n=153) and phase 3 EAGLE (n=247) studies of durvalumab with or without tremelimumab in platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma, published in the Clinical Cancer Research.
11 Sep 2020 Status changed from active, no longer recruiting to completed.
27 Aug 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com